



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
August 7, 2020
9 A.M.

Virtual Meeting—Webex Link Provided Below

1. Call to Order—Chair
2. Opening Comments—OMPP
3. Approval of Memoranda, Meeting of February 7, 2020
4. Preferred Drug List: Therapeutic Class Re-Review
 - a) CNS and Others
 - i. Agents for the Treatment of Opiate Addiction
 - ii. Antiemetic/Antivertigo Agents
 - iii. Antiseizure Agents
 - iv. Gastroprotective NSAIDs
 - v. Narcotic Antitussive/1st Generation Antihistamine Combinations
 - vi. Narcotics
 - vii. Skeletal Muscle Relaxants
 - viii. Smoking Deterrent Agents
 - b) Dermatologic Agents
 - i. Acne Agents
 - ii. Antipsoriatic Agents
 - c) Endocrine
 - i. Anaphylaxis Agents



- ii. Bone Formation Stimulating Agents
 - iii. Bone Resorption Inhibitors
 - iv. DPP4 Inhibitors and Combination Agents
 - v. GLP-1 Receptor Agonists and Combinations
 - vi. Growth Hormones
 - vii. Injectable Hypoglycemics, Insulin
 - viii. Miscellaneous Oral Antidiabetic Agents
 - ix. SGLT2 Inhibitors and Combinations
 - x. Testosterones
- d) Estrogen and Related Agents
- i. Estrogen and Related Agents
- e) Gastrointestinal Agents
- i. Anti-ulcer Agents
 - ii. *H. Pylori* Agents
 - iii. H2 Receptor Antagonists
 - iv. Laxatives and Cathartics
 - v. Pancreatic Enzymes
 - vi. Proton Pump Inhibitors
 - vii. Ulcerative Colitis Agents
- f) Genitourinary Agents
- i. Benign Prostatic Hypertrophy Agents
 - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g) Hematologic Agents
- i. Direct Factor Xa Inhibitors
 - ii. Direct Thrombin Inhibitors
 - iii. Hematinics
 - iv. Heparin and Related Products
 - v. Leukocyte (WBC) Stimulants
 - vi. Platelet Aggregation Inhibitors
- h) Targeted Immunomodulators
- i) Topical Agents
- i. Miotics-Intraocular Pressure Reducers

- ii. Ophthalmic Antihistamines
- iii. Ophthalmic Anti-Inflammatory Agents
- iv. Ophthalmic Anti-Inflammatory Agents, Immunomodulator-Type
- v. Ophthalmic Mast Cell Stabilizers
- vi. Otic Preparations
- vii. Topical Anti-Inflammatory Agents-NSAIDs
- viii. Topical Antiparasitics
- ix. Topical Immunomodulators
- x. Topical Postherpetic Neuralgia Agents
- xi. Wound Care Products

j) Respiratory

- i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
- ii. Antiviral Monoclonal Antibodies
- iii. Beta Adrenergics and Corticosteroids
- iv. Beta Agonists
- v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
- vi. Leukotriene Receptor Antagonists
- vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
- viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
- ix. Oral Inhaled Glucocorticoids
- x. Phosphodiesterase-4 Inhibitors
- xi. Pulmonary Antihypertensives

k) Anti-Infectives

- i. Antivirals - Anti-Herpetic Agents
- ii. Antivirals - Influenza Agents
- iii. Cephalosporins - 3rd Generation
- iv. Fluoroquinolones
- v. Hepatitis C Agents
- vi. Macrolides

- vii. Ophthalmic Antibiotics
- viii. Ophthalmic Antibiotics/Corticosteroid Combinations
 - ix. Oral Non-Systemic Antifungals
 - x. Otic Antibiotics
 - xi. Systemic Antifungals
 - xii. Topical Antifungals
- xiii. Topical Antivirals
- xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
- xv. Vaginal Antimicrobials
- l) Cardiovascular
 - i. Angiotensin-Converting Enzyme (ACE) Inhibitors
 - ii. ACE Inhibitor Combinations
 - iii. Alpha Adrenergic Blockers
 - iv. Angiotensin II Receptor Antagonists (ARBs)
 - v. ARB Combinations
 - vi. Beta Adrenergic Blockers
 - vii. Beta Adrenergic Blockers with Diuretics
 - viii. Calcium Channel Blockers (CCBs)
 - ix. CCBs with HMG-CoA Reductase Inhibitors
 - x. Miscellaneous Cardiac Agents
- m) Lipotropics
 - i. Bile Acid Sequestrants
 - ii. Fibric Acid Derivatives
 - iii. HMG-CoA Reductase Inhibitors
 - iv. Lipotropics
- n) Antimigraine Agents
- o) Electrolyte Depleters
- p) Multiple Sclerosis Agents

5. New Business

6. Public Comment

7. Other Business

8. Adjourn

Meeting number (access code): 161 700 9239

Meeting password: RxMR26B3X5\$

[Join meeting](#)

<https://optum.webex.com/mw3300/mywebex/default.do?siteurl=optum&AT=HM&ST=SUCCESS&MK=1617009239&rnd=0.5104514640686101>

Join by phone

Tap to call in from a mobile device (attendees only)

[1-763-957-6300](tel:1-763-957-6300) US/Canada (Preferred)

[Global call-in numbers](#)